AlphAIAlphAI — Financial news for AI agents
finance.yahoo.comSEP 282 min read$ROIV

Roivant Sciences Targets LISRAYA Launch, Key Pipeline Readouts in Next 12 Months

Roivant Sciences (NASDAQ:ROIV) anticipates updates on IMVT-1402, including Phase II data for rheumatoid arthritis and lupus, and a 2027 catalyst for Graves' disease. The company is also reassessing indications for mosliciguat post-Phase II results. Roivant aims to grow its pipeline but may consider asset sales for attractive offers.

Original reporting
finance.yahoo.com
Published Sep 28, 2026, 8:02 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 28, 2026, 8:58 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Roivant Sciences Targets LISRAYA Launch, Key Pipeline Readouts in Next 12 Months — source image
Source · finance.yahoo.com
Decision brief

The 30-second read

$ROIVNeutralLow
01

Why it matters

The piece is a forward‑looking preview without new quantitative disclosures, limiting immediate trading relevance.

02

Market read

The article provides a schedule of upcoming trial readouts but no new data, resulting in low immediate trading relevance.

03

What to watch

Potential partnership or licensing deals not mentioned could add upside.

Relevance 4/10Novelty 2/10Timing: later this year and into 2027

Background

Roivant Sciences (NASDAQ:ROIV) is a biopharma company developing multiple immunology programs through its Immunovant subsidiary.

Company-level read

Ticker impact

$ROIVNeutralLow confidence
Context

The article outlines Roivant Sciences' upcoming Phase II/III readouts for its Immunovant programs and potential pipeline milestones over the next 12 months.

Expected impact

potential pressure as investors price in uncertainty around trial outcomes

Evidence & confidence

Only forward‑looking statements are provided; no new trial data or regulatory decisions are reported.

Market effects

Sector

Highlights continued activity in the autoimmune and rare‑disease biotech space, but no immediate sector shift.

Regional

Limited to U.S. biotech investors; no broader regional effect.

Global

Minimal global impact; primarily of interest to Roivant shareholders and biotech analysts.

Counterpoint

What could challenge this read

If the upcoming data exceed expectations, the stock could rally sharply, contrary to the neutral outlook.

Key entities

  • company
    Roivant Sciences

    Biopharma firm developing Immunovant pipeline.

  • subsidiary
    Immunovant

    Roivant's unit focused on autoimmune disease programs.

Read at source← All news

Related articles

OCT 5
$ROIVMedAI 8/10

Transcript: Roivant Sciences Q1 2027 Earnings Conference Call - Roivant Sciences (NASDAQ:ROIV)

Roivant Sciences (ROIV) reported Q1 2026 results, highlighting a quiet quarter with progress in its pipeline, particularly brepocitinib's Phase 3 study. The company received a $950M settlement from Moderna and has ongoing litigation against Pfizer and BioNTech. Financially, ROIV reported $200M in R&D expenses, $100M in non-GAAP G&A expenses, and a cash position of nearly $4B. Management expects a busy second half with brepocitinib's launch and other pipeline updates.

benzinga.com3 min
OCT 5
Med

Roivant, the ‘inveterate drug hunters’, enters commercial era with Lisraya

Roivant Sciences, a biopharma company with a unique hub-and-spoke model, is transitioning into a commercial phase with the launch of Lisraya, an oral TYK2/JAK inhibitor for dermatomyositis. CEO Matt Gline aims to differentiate the company with a commercial portfolio, including Lisraya, Pulmovant’s mosliciguat, and Immunovant’s IMVT-1402. Leerink Partners estimates Lisraya could generate $7.9 billion in sales by 2035, with mosliciguat's expectations raised to $9.8 billion.

biospace.com3 min
SEP 24
$ROIVMedAI 8/10

Roivant’s Lung Drug Clears Phase 2 Test: Is Another Major Pipeline Asset Emerging?

Roivant Sciences (ROIV) shares rose 17% after reporting positive Phase 2 results for mosliciguat, its experimental treatment for pulmonary hypertension. The drug met primary and secondary endpoints, reducing pulmonary vascular resistance by 56.3% and improving six-minute walk distance. J.P. Morgan estimates peak sales of $1.5B, though this is an analyst forecast. Roivant is now advancing to Phase 3 trials.

insidermonkey.com3 min